James Clemmer

“If there is one theme that I want you to take away from fiscal 2026, it is this. We are delivering above market profitable growth consistently. We are taking share in the markets we set out to win and we are doing it while expanding profitability and proving that the business can generate positive cash flow.”

— From AngioDynamics Q4 2026 Earnings Call | Medtech Software Sourcing Scales Active Device Margin, i101 (July 14, 2026)

“As I shared then after a decade with our company, I intend to retire and the board is running a comprehensive search with help from a leading executive search firm to identify our next CEO which we expect to occur during the first half of fiscal 2027.”

— From AngioDynamics Q4 2026 Earnings Call | Medtech Software Sourcing Scales Active Device Margin, i101 (July 14, 2026)

“We devested some assets that actually provided revenue and profit for the company. It's hard to do that, but we really knew that was not our future. We had a couple ideas how we could be a science-driven technology company focused on two key areas which are the largest causes of mortality in the globe which are cancer...”

— From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer, IEEE EMBS (December 01, 2025)

“We embarked on a study a few years ago called Preserve to show that the product can be used safely and effectively to treat men with intermediate risk prostate cancer. So we wanted to give the population between that another option to be treated using our nano knife, which our study proved could treat the organ, contro...”

— From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer, IEEE EMBS (December 01, 2025)

“About two months earlier in October, they actually approved our CPT-1 code, which takes effect January 1 of 26, really close to now. That was amazing. I've been doing this over 30 years. I've never heard of a company that actually got their CPT-1 code approved before their 510K was approved. But that showed how effecti...”

— From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer, IEEE EMBS (December 01, 2025)

“We wanted to go right to a CPT-1 code. We know it can be challenging, but we really wanted to make sure there was significant physician reimbursement along with the facility reimbursement together, get that alignment together. And there are other companies and other technologies that have been introduced in what's call...”

— From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer, IEEE EMBS (December 01, 2025)

“I wish I was bolder sooner. I wish I moved faster sooner. The example here at Angio which became real when I joined the company the nano knife project was really focused on treating people with pancreatic cancer... we had to kind of shift gears and said, 'Okay, guys, we'll do what we can.' We developed a registry appro...”

— From IEEE Pulse Industry Corner Live Interview with AngioDynamics CEO Jim Clemmer, IEEE EMBS (December 01, 2025)

“Angiodnamics, a medical technology pioneer, is set to make waves at the UBS Global Healthcare Conference on November 10th, 2025.”

— From AngioDynamics CEO Fireside Chat at UBS Global Healthcare Conference 2025, Infinite Ideas Network (October 28, 2025)

“Their focus, restoring healthy blood flow and expanding treatment options for cancer patients, highlights their commitment to improving quality of life through innovative technologies.”

— From AngioDynamics CEO Fireside Chat at UBS Global Healthcare Conference 2025, Infinite Ideas Network (October 28, 2025)

“Angiodnamics products are chosen by top physicians to address unmet patient needs, demonstrating their impact in fast-growing healthcare markets.”

— From AngioDynamics CEO Fireside Chat at UBS Global Healthcare Conference 2025, Infinite Ideas Network (October 28, 2025)

“The impact of these advancements extends far beyond the conference room. It's about real people, real lives, and real hope.”

— From AngioDynamics CEO Fireside Chat at UBS Global Healthcare Conference 2025, Infinite Ideas Network (October 28, 2025)

“With their dedication to innovation and patient-centric care, they're shaping the future of vascular health and cancer treatment.”

— From AngioDynamics CEO Fireside Chat at UBS Global Healthcare Conference 2025, Infinite Ideas Network (October 28, 2025)

“So we decided in 2019 Omar to divest our largest single business at the time but it had become kind of commoditized and less special and we weren't able to compete with the really large players in the space.”

— From Building a Stronger & Better AngioDynamics, MDDI (September 02, 2025)

“We bought the company and a year later we launched the product. The results we just reported had over $55 million of revenue and only our fourth year.”

— From Building a Stronger & Better AngioDynamics, MDDI (September 02, 2025)

“The XMO company we bought had zero revenue. We had a great product, but no one ever bought one. So, we had to take a risk here.”

— From Building a Stronger & Better AngioDynamics, MDDI (September 02, 2025)